Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements - Novartis (Details)

v3.20.4
Collaborative Arrangements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
May 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contract liabilities, deferred revenue   $ 4,791 $ 2,044  
Novartis        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Term of collaborative research and development agreement 25 months      
Contract liabilities, deferred revenue $ 5,000      
Liability, revenue recognized   6,200 $ 11,300  
Novartis | Computer equipment and software        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contingent annual receivable increase 8,000      
Novartis | Milestone One        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contingent receivable   $ 3,400   $ 4,000
Novartis | Milestone Two        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contingent receivable $ 1,600